By Drug Type, Liraglutide Segment Accounts for 35.5% Market Share The liraglutide segment is projected to account for 35.5% of the GLP-1 diabetes treatment drugs market in 2025, reaffirming its position as the leading drug type category
Pharmacotherapy for gestational diabetes
"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial"
The dosage and administration of Tirzepatide / Niacinamide Injection requires careful individualization based on patient characteristics and tolerance to therapy, as determined by the prescribing clinician
Daytime impairment from sleep deprivation that affects work performance, driving safety, or daily functioning should not be tolerated as a medication side effect
The platform's cash-pay model removes insurance barriers for consumers seeking access to these medications, and the availability of multiple delivery formats gives consumers flexibility in how they receive treatment